Home › Leucemia linfatica cronica › North Carolina
Studi clinici su Leucemia linfatica cronica nello stato di North Carolina
34 studi su Leucemia linfatica cronica cercano partecipanti presso sedi nello stato di North Carolina.
Città nello stato di North Carolina
Testo ufficiale dello studio (inglese)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- Margaret R Pardee Memorial Hospital, Hendersonville
In reclutamentoFase 3
Età 65 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- e altri 6
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Charlotte
- Research Site, Winston-Salem
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- e altri 5
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 109, Greenville
- GC2202 Decentralized Study Site 114, Morrisville
- GC2202 Study Site 117, Wilson
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- University of North Carolina At Chapel Hill, Chapel Hill
- Levine Cancer Center, Charlotte
- Atrium Health Wake Forest Baptist, Winston-Salem
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Atrium Health Levine Cancer Institute (Lci), Charlotte
- Duke University Medical Center, Durham
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of North Carolina At Chapel Hill, Chapel Hill
- Atrium Health Levine Cancer Institute (Lci), Charlotte
- Duke University Medical Center, Durham
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Carolina Oncology Specialists, PA ( Site 0054), Charlotte
- Southeastern Medical Oncology Center ( Site 0049), Goldsboro
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Duke University, Durham
- Novant Health Cancer Institute, Winston-Salem
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07221500Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07061951A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Charlotte
- Research Site, Charlotte
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06564038Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT04588922Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
In reclutamentoFase 1/2
Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
- Research Site, Charlotte
- Research Site, Durham
- Research Site, Winston-Salem
In reclutamentoFase 2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT07024706A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 31 lug 2026 · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 lug 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 lug 2026 · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- e altri 4
In reclutamentoStudio osservazionale
Età 65 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT01137825A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- East Carolina University, Greenville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 mag 2026 · NCT06588478Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
In reclutamentoFase 1
Età 13 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04771572The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
In reclutamentoStudio osservazionale
Età da 18 a 120 · Tutti i sessi · Aggiornato il 13 apr 2026 · NCT01890486A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Atrium Health /ID# 267219, Charlotte
- Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 apr 2026 · NCT06428019A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Duke University Medical Center, Durham
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Duke University Medical Center, Durham
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- University of North Carolina /ID# 233313, Chapel Hill
- Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
- Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 feb 2026 · NCT04895436Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- The University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 gen 2026 · NCT06043674AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 dic 2025 · NCT05602363Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
In reclutamentoStudio osservazionale
Età da 18 a 120 · Tutti i sessi · Aggiornato il 27 ott 2025 · NCT01137643A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Durham VA Medical Center, Durham, NC, Durham
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 14 ott 2025 · NCT06520098A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2025 · NCT05780034CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Duke University, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 lug 2025 · NCT04704323Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.